| pubmed-article:3238874 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3238874 | lifeskim:mentions | umls-concept:C0007450 | lld:lifeskim |
| pubmed-article:3238874 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:3238874 | lifeskim:mentions | umls-concept:C0013125 | lld:lifeskim |
| pubmed-article:3238874 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3238874 | pubmed:dateCreated | 1989-4-24 | lld:pubmed |
| pubmed-article:3238874 | pubmed:abstractText | The hemodynamic and respiratory effects of three doses (9.7, 15.8, and 23.7 mg/kg intravenous [IV]) of a 1:1 combination of tiletamine and zolazepam were studied after isoflurane anesthesia in cats instrumented for the recording of hemodynamic data. Systolic, mean, and diastolic arterial blood pressures were decreased 1 minute after drug administration but then increased above baseline with all three doses. Cardiac output was decreased briefly at 1 minute with the 15.8 and 23.7 mg/kg doses. The rate of development of left ventricular pressure and peripheral vascular resistance decreased at 1 minute but returned to baseline or above by 10 minutes. There were no significant changes in heart rate, central venous pressure, or left ventricular end diastolic pressure. The arterial pH and blood gas measurements reflected the development of respiratory acidosis after administration of 23.7 mg/kg. These results support the conclusions that tiletamine-zolazepam administered intravenously is a useful and comparatively safe anesthetic agent in the cat. | lld:pubmed |
| pubmed-article:3238874 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3238874 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3238874 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3238874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3238874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3238874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3238874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3238874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3238874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3238874 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3238874 | pubmed:issn | 0161-3499 | lld:pubmed |
| pubmed-article:3238874 | pubmed:author | pubmed-author:MuirW WWW3rd | lld:pubmed |
| pubmed-article:3238874 | pubmed:author | pubmed-author:HubbellJ AJA | lld:pubmed |
| pubmed-article:3238874 | pubmed:author | pubmed-author:SallyJJ | lld:pubmed |
| pubmed-article:3238874 | pubmed:author | pubmed-author:HellyerPP | lld:pubmed |
| pubmed-article:3238874 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3238874 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:3238874 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3238874 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3238874 | pubmed:pagination | 105-10 | lld:pubmed |
| pubmed-article:3238874 | pubmed:dateRevised | 2011-4-25 | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:meshHeading | pubmed-meshheading:3238874-... | lld:pubmed |
| pubmed-article:3238874 | pubmed:articleTitle | Cardiorespiratory effects of the intravenous administration of tiletamine-zolazepam to cats. | lld:pubmed |
| pubmed-article:3238874 | pubmed:affiliation | Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Ohio State University, Columbus 43210. | lld:pubmed |
| pubmed-article:3238874 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3238874 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3238874 | lld:pubmed |
